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SynopsisMutations in glycogenin‐1 (*GYG1*) may cause an adult‐onset distal polyglucosan body myopathy.

A 68‐year‐old woman presented with a 10‐year history of distal myopathy predominantly affecting finger extensors and intrinsic hand muscles, with lesser weakness of proximal muscles. Electromyography showed myopathic findings. The creatine kinase level was normal. A muscle biopsy revealed a polyglucosan body myopathy (PGBM, Figure [1](#jmd212129-fig-0001){ref-type="fig"}). Echocardiography was unremarkable. Genetic testing identified two pathogenic variants in *GYG1*: c.143+3G\>C and c.819T\>A, p.Tyr273Ter.

![Deltoid biopsy demonstrating polyglucosan bodies. Haematoxylin and eosin preparation, A, showing large violaceous inclusions containing periodic acid‐Schiff‐positive material; B, resisting α‐amylase treatment; C, suggesting polyglucosan accumulation. Normal glycogen is depleted in fibres with polyglucosan bodies. Electron micrographs showing filamentous structures consistent with polyglucosan (arrowheads, D,E). Scale bar A to C, 50 μm; D, 10 μm; E, 400 nm](JMD2-55-88-g001){#jmd212129-fig-0001}

Polyglucosan is a polysaccharide with a less branched structure than glycogen and which aggregates into polyglucosan bodies. PGBM can stem from mutations in *GBE1*, *GYG1*, or *RBCK1*. Polyglucosan bodies in muscle can also occur in phosphofructokinase deficiency, Lafora disease or PRKAG2‐cardiomyopathy.[^1^](#jmd212129-bib-0001){ref-type="ref"} *GYG1* encodes glycogenin‐1, an enzyme whose autoglycosylation is one of the initial steps of glycogen synthesis. Mutations in *GYG1* cause glycogen storage disease (GSD) XV. c.143+3G\>C is the most common pathogenic variant in *GYG1* and causes skipping of exon 2, leading to a frameshift and nonsense‐mediated decay.[^2^](#jmd212129-bib-0002){ref-type="ref"}, [^3^](#jmd212129-bib-0003){ref-type="ref"} The c.819T\>A variant is novel and located between the catalytic and C‐terminal glycogen synthase‐binding domains. Truncating variants in the catalytic domain result in reduced or absent protein expression, while those in the C‐terminal region result in a protein with reduced glycosylation.[^1^](#jmd212129-bib-0001){ref-type="ref"}, [^2^](#jmd212129-bib-0002){ref-type="ref"}, [^3^](#jmd212129-bib-0003){ref-type="ref"} Like our patient, those carrying the latter variants also presented with distal weakness.[^2^](#jmd212129-bib-0002){ref-type="ref"}, [^3^](#jmd212129-bib-0003){ref-type="ref"}

Age of onset of GSD XV varies widely, ranging from childhood to the 70s.[^2^](#jmd212129-bib-0002){ref-type="ref"}, [^3^](#jmd212129-bib-0003){ref-type="ref"} The disorder most commonly presents with slowly progressive proximal weakness, but scapuloperoneal and distal myopathy have also rarely been reported.[^3^](#jmd212129-bib-0003){ref-type="ref"} Some patients exhibit significantly asymmetric weakness. The distal myopathy phenotype is associated with an older age of onset (40s‐70s).[^3^](#jmd212129-bib-0003){ref-type="ref"} Unlike several other GSDs, exercise intolerance and rhabdomyolysis are not prominent features. Creatine kinase levels are normal or mildly elevated. It has been suggested that polyglucosan bodies in GSD XV are more easily digested by α‐amylase, potentially offering a clue to the diagnosis.[^2^](#jmd212129-bib-0002){ref-type="ref"} *GYG1* is also expressed in cardiac muscle, and cardiomyopathy has occasionally been reported in GSD XV, with or without skeletal muscle involvement.
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